Patient pretreatment characteristics
| Characteristic . | N (%) . |
|---|---|
| Total (N = 295) . | |
| Sex | |
| Male | 180 (61) |
| Female | 115 (39) |
| Race | |
| Unknown | 24 (8.1) |
| White | 220 (74.6) |
| Black/African American | 29 (9.8) |
| Asian | 9 (3.1) |
| Native Hawaiian or Pacific Islander | 2 (0.7) |
| Native American or Alaska native | 7 (2.4) |
| Not reported | 3 (1.0) |
| Multiple races reported | 1 (0.3) |
| Ethnicity | |
| Hispanic | 45 (15.3) |
| Non-Hispanic | 218 (73.9) |
| Not Reported | 4 (1.4) |
| Unknown | 28 (9.5) |
| Age at diagnosis, yr | |
| Median | 24.0 |
| Range | 17.0-39.0 |
| 16-20 | 74 (25.1) |
| 21-29 | 146 (49.5) |
| 30-39 | 75 (25.4) |
| BMI, kg/m2 | |
| Median | 26.5 |
| Range | 14.9-54.3 |
| <30 | 201 (68.1) |
| 30-40 | 72 (24.4) |
| >40 | 22 (7.5) |
| Performance status (ECOG) | |
| 0 | 116 (39.3) |
| 1 | 153 (51.9) |
| 2 | 26 (8.8) |
| Immunophenotype (n = 294) | |
| B cell | 223 (75.9) |
| T cell | 71 (24.1) |
| CNS extramedullary disease (n = 294) | |
| Involved | 31 (10.5) |
| Not involved | 255 (86.4) |
| Unknown | 8 (2.7) |
| Not done | 24 (8.2) |
| WBC, ×109/L (n = 292) | |
| Median | 9 |
| Range | 0.4-444.6 |
| ≤30 | 217 (74.3) |
| >30 | 75 (25.7) |
| Ph-like genetic profile (n = 131) | |
| Yes | 41 (31.3) |
| No | 90 (68.7) |
| Aberrant CRLF2 expression (n = 131) | |
| Yes | 28 (21.4) |
| No | 103 (78.6) |
| Cytogenetics6 (n = 257) | |
| Favorable | 16 (6.2) |
| Intermediate | 112 (43.6) |
| Unfavorable | 18 (7.0) |
| Unclassified | 25 (9.8) |
| Not fully evaluable | 86 (33.5) |
| Characteristic . | N (%) . |
|---|---|
| Total (N = 295) . | |
| Sex | |
| Male | 180 (61) |
| Female | 115 (39) |
| Race | |
| Unknown | 24 (8.1) |
| White | 220 (74.6) |
| Black/African American | 29 (9.8) |
| Asian | 9 (3.1) |
| Native Hawaiian or Pacific Islander | 2 (0.7) |
| Native American or Alaska native | 7 (2.4) |
| Not reported | 3 (1.0) |
| Multiple races reported | 1 (0.3) |
| Ethnicity | |
| Hispanic | 45 (15.3) |
| Non-Hispanic | 218 (73.9) |
| Not Reported | 4 (1.4) |
| Unknown | 28 (9.5) |
| Age at diagnosis, yr | |
| Median | 24.0 |
| Range | 17.0-39.0 |
| 16-20 | 74 (25.1) |
| 21-29 | 146 (49.5) |
| 30-39 | 75 (25.4) |
| BMI, kg/m2 | |
| Median | 26.5 |
| Range | 14.9-54.3 |
| <30 | 201 (68.1) |
| 30-40 | 72 (24.4) |
| >40 | 22 (7.5) |
| Performance status (ECOG) | |
| 0 | 116 (39.3) |
| 1 | 153 (51.9) |
| 2 | 26 (8.8) |
| Immunophenotype (n = 294) | |
| B cell | 223 (75.9) |
| T cell | 71 (24.1) |
| CNS extramedullary disease (n = 294) | |
| Involved | 31 (10.5) |
| Not involved | 255 (86.4) |
| Unknown | 8 (2.7) |
| Not done | 24 (8.2) |
| WBC, ×109/L (n = 292) | |
| Median | 9 |
| Range | 0.4-444.6 |
| ≤30 | 217 (74.3) |
| >30 | 75 (25.7) |
| Ph-like genetic profile (n = 131) | |
| Yes | 41 (31.3) |
| No | 90 (68.7) |
| Aberrant CRLF2 expression (n = 131) | |
| Yes | 28 (21.4) |
| No | 103 (78.6) |
| Cytogenetics6 (n = 257) | |
| Favorable | 16 (6.2) |
| Intermediate | 112 (43.6) |
| Unfavorable | 18 (7.0) |
| Unclassified | 25 (9.8) |
| Not fully evaluable | 86 (33.5) |